rivaroxaban in patients stabilized after a st-segment elevation myocardial infarction - results from...
TRANSCRIPT
-
8/10/2019 Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction - Results From the ATLAS ACS-2TIMI-51 Trial (Anti-Xa Therapy to Low
1/7
-
8/10/2019 Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction - Results From the ATLAS ACS-2TIMI-51 Trial (Anti-Xa Therapy to Low
2/7
-
8/10/2019 Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction - Results From the ATLAS ACS-2TIMI-51 Trial (Anti-Xa Therapy to Low
3/7
-
8/10/2019 Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction - Results From the ATLAS ACS-2TIMI-51 Trial (Anti-Xa Therapy to Low
4/7
-
8/10/2019 Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction - Results From the ATLAS ACS-2TIMI-51 Trial (Anti-Xa Therapy to Low
5/7
-
8/10/2019 Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction - Results From the ATLAS ACS-2TIMI-51 Trial (Anti-Xa Therapy to Low
6/7
-
8/10/2019 Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction - Results From the ATLAS ACS-2TIMI-51 Trial (Anti-Xa Therapy to Low
7/7